Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd
-(BIOCON)
XNSE:BIOCON, XBOM:BIOCON
Biocon Ltd Q1FY25; 479% rise in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q1FY25
Biocon Ltd Q4FY24; 46% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q3FY24; 34% rise in Revenue
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q3FY24
Biocon Ltd Q2FY24; 111% rise in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q2FY24
Biocon Ltd Q1FY24; 11% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd.: Driving Growth in Pharmaceutical Industry.
Stock Data: TickerNSE: BIOCONExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+1.43%YTD-7.18%Last 12 Months-22.16%As on 16-06-2023 Company Description: Biocon is India's premier biotechnology company. It
Alphagraph | Biocon Limited (NSE: BIOCON): Q4FY23 Results Out; Total Income rises 58% YoY.
Biocon is a prominent player in the biotechnology industry, specializing in the manufacturing of biotechnology products and offering research services. With a
Biocon Limited (BIOCON) Q3 FY23 Earnings Concall Transcript
Biocon Limited (NSE:BIOCON) Q3 FY23 Earnings Concall dated Feb. 15, 2023. Corporate Participants: Saurabh Paliwal -- Head - Investor Relations Kiran Mazumdar Shaw -- Biocon Ltd.
Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY
Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by Kiran Mazumdar-Shaw
Biocon Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Q&A Highlights: [00:23:49] Prakash Agarwal of Axis Capital asked about the mezzanine
Biocon Q2FY23 results out: Revenue up by 26%
Biocon Ltd reported a 49 percent slump in consolidated net profit at INR 82 crore for the quarter ended September 30, 2022.
Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE:BIOCON) Q1 FY23 Earnings Concall dated Jul. 27, 2022. Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and Biocon Biologics
Infographic: Biocon opens this year with a stellar performance reporting 71% growth in profits
Biocon on Wednesday reported 71% year-on-year (YoY) jump in net profit to Rs 144 crore during Q1FY23, driven by sales of biosimilar
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE : BIOCON) Q1 FY23 Earnings Concall dated July. 27, 2022 Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and
Biocon Limited (BIOCON) Q4 2022 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q4 2022 earnings concall dated Apr. 29, 2022 Corporate Participants: Aishwarya Seetharam -- Head, Investor Relations Kiran Mazumdar Shaw -- Executive Chairperson
Biocon Ltd (BIOCON) Q3 FY22 Earnings Concall Transcript
Biocon Limited (NSE:BIOCON) Q3 FY22 Earnings Concall dated Jan. 20, 2022 Corporate participants: Aishwarya Sitharam -- Head of Investor Relations Kiran Mazumdar